Inicio › Leucemia mielógena aguda › Carolina del Norte

Ensayos clínicos de Leucemia mielógena aguda en Carolina del Norte

43 estudios sobre Leucemia mielógena aguda buscan participantes en Carolina del Norte.

Ciudades en Carolina del Norte

Texto oficial del estudio (inglés)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Carolinas Medical Center/Levine Cancer Institute, Charlotte
Novant Health Presbyterian Medical Center, Charlotte
y 5 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

AdventHealth Infusion Center Asheville, Asheville
Southeastern Medical Oncology Center-Clinton, Clinton
AdventHealth Infusion Center Haywood, Clyde
y 6 más

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 2 oct 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Wake Forest University Health Sciences, Winston-Salem

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Carolinas Medical Center/Levine Cancer Institute, Charlotte
Novant Health Presbyterian Medical Center, Charlotte
Duke University Medical Center, Durham
y 3 más

ReclutandoFase 2

Edades de 18 a 59 · Todos los sexos · Actualizado el 28 sept 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Atrium Health, Charlotte
Novant Health Charlotte, Charlotte
Carolina Oncology Specialists, Charlotte
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06852222

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Carolinas Medical Center/Levine Cancer Institute, Charlotte
Duke University Medical Center, Durham
East Carolina University, Greenville
y 1 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Carolinas Medical Center/Levine Cancer Institute, Charlotte
Duke University Medical Center, Durham
East Carolina University, Greenville
y 1 más

ReclutandoFase 2

Edades de 18 a 59 · Todos los sexos · Actualizado el 22 sept 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Carolinas Medical Center/Levine Cancer Institute, Charlotte
Duke University Medical Center, Durham
East Carolina University, Greenville
y 1 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Mission Hospital, Asheville
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Carolinas Medical Center/Levine Cancer Institute, Charlotte
y 4 más

ReclutandoFase 3

6 Months – 21 Years · Todos los sexos · Actualizado el 17 sept 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Duke University Medical Center, Durham

ReclutandoFase 1/2

30 Days · Todos los sexos · Actualizado el 16 sept 2026 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Novant Health Clinical Research, Charlotte
East Carolina University, Greenville

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT06824168

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

University of North Carolina at Chapel Hill, Chapel Hill

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06846606

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

UNC School of Medicine, Division of Hematology, Chapel Hill

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT04588922

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Atrium Health Wake Forest Baptist Medical Center, Winston-Salem

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07471841

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06652438

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Novant Health Weisiger Cancer Institute, Charlotte

ReclutandoEstudio observacional

Edades de 0 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07154823

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Mission Hospital, Asheville
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Carolinas Medical Center/Levine Cancer Institute, Charlotte
y 4 más

ReclutandoFase 1/2

Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Carolinas Medical Center/Levine Cancer Institute, Charlotte
Wake Forest University Health Sciences, Winston-Salem

ReclutandoFase 1

Edades de 18 a 75 · Todos los sexos · Actualizado el 25 ago 2026 · NCT05886049

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of North Carolina, Chapel Hill, Chapel Hill
Duke University Medical Center, Durham

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Atrium Health Levine Cancer Center, Charlotte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

University of North Carolina at Chapel Hill, Chapel Hill

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06656494

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Levine Cancer Institute, Charlotte
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 jul 2026 · NCT06580106

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Levine Cancer Insitute, Charlotte
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

Reclutando

Edades de 18 a 64 · Todos los sexos · Actualizado el 23 jul 2026 · NCT06945042

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Research Site, Chapel Hill
Research Site, Durham

ReclutandoFase 1/2

Edades de 16 en adelante · Todos los sexos · Actualizado el 20 jul 2026 · NCT07155226

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

University of North Carolina at Chapel Hill, Chapel Hill
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

University of North Carolina at Chapel Hill, Chapel Hill
Levine Children's Hospital, Charlotte
Duke University Medical Center, Durham

ReclutandoEstudio observacional

Todas las edades · Todos los sexos · Actualizado el 6 jul 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem

Reclutando

Edades de 60 en adelante · Todos los sexos · Actualizado el 6 jul 2026 · NCT06697600

Registry of Older Patients With Cancer

Seby B. Jones Cancer Center, Boone
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
East Carolina University, Greenville
y 4 más

ReclutandoEstudio observacional

Edades de 65 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT01137825

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT05401097

A Study of Revumenib and Mezigdomide in People With Leukemia

University of North Carolina (Data Collection Only), Chapel Hill

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 22 jun 2026 · NCT07356154

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 may 2026 · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

University of North Carolina, Chapel Hill

ReclutandoFase 1

Edades de 13 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Duke University, Durham

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 abr 2026 · NCT04256317

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Wake Forest Baptist Health, Winston-Salem

ReclutandoEstudio observacional

Edades de 18 a 120 · Todos los sexos · Actualizado el 13 abr 2026 · NCT01890486

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

UNC Hospital, Chapel Hill
Duke University, Durham
Atrium Wake Forest Baptist Medical Center, Winston-Salem

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT04988555

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

University of North Carolina, Chapel Hill

ReclutandoFase 2

Edades de 18 a 66 · Todos los sexos · Actualizado el 17 mar 2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Duke Blood Cancer Center, Durham

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT05735184

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Duke Cancer Center, Durham

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 ene 2026 · NCT05143996

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Novant Health Cancer Institute, Charlotte
Novant Health Cancer Institute, Winston-Salem

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 dic 2025 · NCT06680752

Novel Digital Application for Patients With Acute Leukemia

Duke University, Durham

Reclutando

Edades de 18 a 120 · Todos los sexos · Actualizado el 10 nov 2025 · NCT06472128

De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.